TRAF6-driven inflammation that ultimately leads to neuronal death in AD is mediated by NF-κB and MAPK signaling pathways, indicating that TRAF6 inhibition may be beneficial to AD patients. The gene discussed is NFKB1; the disease is Alzheimer disease.